Phase I Study of EOS789
Latest Information Update: 15 Dec 2017
At a glance
- Drugs EOS 789 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 30 Jun 2016 Status changed from recruiting to discontinued.
- 08 Jun 2016 New trial record
- 24 Sep 2015 Status changed from not yet recruiting to recruiting.